TheProfitWatch

PBYI - PUMA BIOTECHNOLOGY INC

Day 1m 10m 60m PreMarket Market AfterHours Gap
5.48 0.02 (0.3%) --- --- --- 0.02 (0.3%) 0.16 (2.9%) 0.0 (0.0%) 0.0 (0.0%)

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Closed

Earnings & Ratios

Basic EPS:
0.12
Diluted EPS:
0.12
Basic P/E:
45.8333
Diluted P/E:
45.8333
RSI(14) 1m:
100.0
VWAP:
5.5
RVol:
0.6213

Events

Period Kind Movement Occurred At
1m Price increase 1m 5.37 +0.06 (+1.13%) Oct 15 12:40

Related News